KYMR Q4 2024 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-84.6% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$81M-1092.2% margin

Net Income

-$71M-956.9% margin

EPS (Diluted)

$-0.88

QoQ Revenue Growth

+97.6%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$63M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$978M

Total Liabilities

$142M

Stockholders' Equity

$836M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$48M	-84.6%
Gross Profit	$7M	$48M	-84.6%
Operating Income	-$81M	-$19M	-318.2%
Net Income	-$71M	-$14M	-392.4%